Free Publications

Search for all returned 3 results

Heart Disease in Lymphoma Survivors

  Matthew Matasar is a hematology and oncology specialist at Memorial Sloan-Kettering Cancer Center in New York City. He has a Translational Research Program grant through The Leukemia & Lymphoma Society and is investigating which Hodgkin lymphoma survivors are at greater risk for developing heart disease after receiving radiation therapy to the chest and what diagnostic tests are best.   What kind of research do you do? There’s been a lot of ...

Read more

Achieving the Impossible: What’s ahead in 2018?

We’ve just concluded one of the most historic years on record in terms of new therapy approvals for blood cancers. In all, the U.S. Food and Drug Administration (FDA) approved 18 therapies to treat patients with blood cancers, including some entirely new agents and some new uses for already approved drugs. Among these approvals were the first new therapies – four to be precise – for acute myeloid leukemia (AML) after a 40-year drought in treatment advances for this deadly blood ...

Read more

FDA Update: New Therapy for Hodgkin Lymphoma Patients

The U.S. Food and Drug Administration (FDA) approved an immunotherapy for adults and children with classical Hodgkin lymphoma who were not benefiting from existing treatments. The Leukemia & Lymphoma Society (LLS) applauds this approval as an important step forward in ultimately finding a cure for these patients. While Hodgkin lymphoma is now considered one of the most curable forms of cancer – with a more than 88 percent five-year-survival rate overall – this therapy is for pati ...

Read more